Espectrometría infrarroja con array de fotodetectores

Peer Reviewe

The validity and reliability of a new instrumented device for measuring ankle dorsiflexion range of motion

PURPOSE/BACKGROUND: A restriction in ankle dorsiflexion range of motion (ROM) has been linked to several clinical manifestations such as metatarsalgia, heel pain, nerve entrapment, ankle joint equinus, patellar and ankle injuries. The purpose of the present study was to examine the validity and reliability of the Leg Motion system for measuring ankle dorsiflexion ROM. STUDY DESIGN: Descriptive repeated-measures study. METHODS: Twenty-six healthy male university students were recruited to test the reliability of the Leg Motion system, which is a portable tool used for assessment of ankle dorsiflexion during the weight-bearing lunge test. The participants were tested two times separated by two weeks and measurements were performed at the same time of the day by the same single rater. To test the validity of the Leg Motion system, other maximal ankle dorsiflexion ROM assessments (goniometer, inclinometer and measuring tape) were measured in a single session (i.e., the first test session) during the weight-bearing lunge position using a standard goniometer, a digital inclinometer and a measuring tape measure with the ability to measure to the nearest 0.1 cm. RESULTS: Paired t-tests showed the absence of significant differences between right and left limb measurements of dorsiflexion in all tests. Mean values ± standard deviations were as follows: Leg Motion test (left 11.6cm±3.9; right 11.9cm ±4.0), tape measure (left 11.6cm±4.0; right 11.8cm±4.2), goniometer (left 40.6º±5.2; right 40.6º±5.2), and digital inclinometer (left 40.0º±5.8; right 39.9º±5.6). The Leg Motion composite values (i.e., average of the two legs) showed a significant (p<0.05) positive correlation with the tape measure (r=0.99), with the goniometer (r=0.66), and with the digital inclinometer (r=0.72). CONCLUSIONS: The results of the present study provide evidence to support the use of the Leg Motion system as a valid, portable, and easy to use alternative to the weight-bearing lunge test to assess ankle dorsiflexion ROM in healthy participants

Scalable haloscopes for axion dark matter detection in the 30 µeV range with RADES

RADES (Relic Axion Detector Exploratory Setup) is a project with the goal of directly searching for axion dark matter above the 30μeV scale employing custom-made microwave filters in magnetic dipole fields. Currently RADES is taking data at the LHC dipole of the CAST experiment. In the long term, the RADES cavities are envisioned to take data in the BabyIAXO magnet. In this article we report on the modelling, building and characterisation of an optimised microwave-filter design with alternating irises that exploits maximal coupling to axions while being scalable in length without suffering from mode-mixing. We develop the mathematical formalism and theoretical study which justifies the performance of the chosen design. We also point towards the applicability of this formalism to optimise the MADMAX dielectric haloscopes.We thank Ciaran O’Hare for his generous and publicly available compilation of axion bounds https://github.com/cajohare /AxionLimits/. This work has been funded by the Spanish Ministerio de Economía, Industria y Competitividad – Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) under project FPA-2016-76978, and was supported by the CERN Doctoral Studentship programme. The research leading to these results has received funding from the European Research Council and BD, JG and SAC acknowledge support through the European Research Council under grant ERC-2018-StG-802836 (AxScale project). IGI acknowledges also support from the European Research Council (ERC) under grant ERC-2017-AdG-788781 (IAXO+ project). JR has been supported by the Ramon y Cajal Fellowship 2012-10597, the grant PGC2018-095328-B-I00(FEDER/Agencia estatal de investigaci´on) and FSE-DGA2017-2019-E12/7R (Gobierno de Aragón/FEDER) (MINECO/FEDER), the EU through the ITN “Elusives” H2020-MSCA-ITN-2015/674896 and the Deutsche Forschungsgemeinschaft under grant SFB-1258 as a Mercator Fellow. CPG was supported by PROMETEO II/2014/050 of Generalitat Valenciana, FPA2014-57816-P of MINECO and by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreements 690575 and 674896. AM is supported by the European Research Council under Grant No. 742104. We wish also to thank our colleagues at CAST and at CERN, in particular Marc Thiebert from the coating lab, Sergio Calatroni for many useful discussions, as well as the whole team of the CERN Central Cryogenic Laboratory for their support and advice in specific aspects of the project

Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD). Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity. Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL: 1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Results: Four hundred and thirty-nine PD patients (62.05 +/- 7.84 years old; 59% males) were included. MNCD stage was: stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advanced MNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p < 0.0001) and EUROHIS-QOL8 (p < 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages. Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD

Predictors of Loss of Functional Independence in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group

COPPADIS Study Group.[Background and objective] The aim of this study was to compare the progression of independence in activities of daily living (ADL) in Parkinson’s disease (PD) patients versus a control group, as well as to identify predictors of disability progression and functional dependency (FD).[Patients and Methods] PD patients and control subjects, who were recruited from 35 centers of Spain from the COPPADIS cohort between January 2016 and November 2017 (V0), were included. Patients and subjects were then evaluated again at the 2-year follow-up (V2). Disability was assessed with the Schwab & England Activities of Daily Living Scale (S&E-ADLS) at V0 and V2. FD was defined as an S&E-ADLS score less than 80%.[Results] In the PD group, a significant decrease in the S&E-ADLS score from V0 to V2 (N = 507; from 88.58 ± 10.19 to 84.26 ± 13.38; p < 0.0001; Cohen’s effect size = −0.519) was observed but not in controls (N = 124; from 98.87 ± 6.52 to 99.52 ± 2.15; p = 0.238). When only patients considered functional independent at baseline were included, 55 out of 463 (11.9%) converted to functional dependent at V2. To be a female (OR = 2.908; p = 0.009), have longer disease duration (OR = 1.152; p = 0.002), have a non-tremoric motor phenotype at baseline (OR = 3.574; p = 0.004), have a higher score at baseline in FOGQ (OR = 1.244; p < 0.0001) and BDI-II (OR = 1.080; p = 0.008), have a lower score at baseline in PD-CRS (OR = 0.963; p = 0.008), and have a greater increase in the score from V0 to V2 in UPDRS-IV (OR = 1.168; p = 0.0.29), FOGQ (OR = 1.348; p < 0.0001) and VAFS-Mental (OR = 1.177; p = 0.013) (adjusted R-squared 0.52; Hosmer and Lemeshow test = 0.94) were all found to be independent predictors of FD at V2.[Conclusions] In conclusion, autonomy for ADL worsens in PD patients compared to controls. Cognitive impairment, gait problems, fatigue, depressive symptoms, more advanced disease, and a non-tremor phenotype are independent predictors of FD in the short-term.Fundación Curemos el Parkinson (www.curemoselparkinson.org).Peer reviewe

An Energy-Reduced Mediterranean Diet, Physical Activity, and Body Composition

[ENG]Importance Strategies targeting body composition may help prevent chronic diseases in persons with excess weight, but randomized clinical trials evaluating lifestyle interventions have rarely reported effects on directly quantified body composition. OBJECTIVE To evaluate the effects of a lifestyle weight-loss intervention on changes in overall and regional body composition. DESIGN, SETTING, AND PARTICIPANTS The ongoing Prevención con Dieta Mediterránea-Plus (PREDIMED-Plus) randomized clinical trial is designed to test the effect of the intervention on cardiovascular disease prevention after 8 years of follow-up. The trial is being conducted in 23 Spanish research centers and includes men and women (age 55-75 years) with body mass index between 27 and 40 and metabolic syndrome. The trial reported herein is an interim subgroup analysis of the intermediate outcome body composition after 3-year follow-up, and data analysis was conducted from February 1 to November 30, 2022. Of 6874 total PREDIMED-Plus participants, a subsample of 1521 individuals, coming from centers with access to a dual energy x-ray absorptiometry device, underwent body composition measurements at 3 time points. INTERVENTION Participants were randomly allocated to a multifactorial intervention based on an energy-reduced Mediterranean diet (MedDiet) and increased physical activity (PA) or to a control group based on usual care, with advice to follow an ad libitum MedDiet, but no physical activity promotion. MAIN OUTCOMES AND MEASURES The outcomes (continuous) were 3-year changes in total fat and lean mass (expressed as percentages of body mass) and visceral fat (in grams), tested using multivariable linear mixed-effects models. Clinical relevance of changes in body components (dichotomous) was assessed based on 5% or more improvements in baseline values, using logistic regression. Main analyses were performed in the evaluable population (completers only) and in sensitivity analyses, multiple imputation was performed to include data of participants lost to follow-up (intention-to-treat analyses). RESULTS A total of 1521 individuals were included (mean [SD] age, 65.3 [5.0] years; 52.1% men). In comparison with the control group (n=761), participants in the intervention arm (n=760) showed greater reductions in the percentage of total fat (between group differences after 1-year, −0.94% [95% CI, −1.19 to −0.69]; 3 years, −0.38% [95% CI, −0.64 to −0.12] and visceral fat storage after 1 year, -126 g [95% CI, −179 to −73.3 g]; 3 years, −70.4 g [95% CI, −126 to −15.2 g] and greater increases in the percentage of total lean mass at 1 year, 0.88% [95% CI, 0.63%-1.12%]; 3-years 0.34% [95%CI, 0.09%-0.60%]). The intervention group was more likely to show improvements of 5% or more in baseline body components (absolute risk reduction after 1 year, 13% for total fat mass, 11% for total lean mass, and 14% for visceral fat mass; after 3-years: 6% for total fat mass, 6% for total lean mass, and 8% for visceral fat mass). The number of participants needed to treat was between 12 and 17 to attain at least 1 individual with possibly clinically meaningful improvements in body composition. CONCLUSIONS AND RELEVANCE The findings of this trial suggest a weight-loss lifestyle intervention based on an energy-reduced MedDiet and physical activity significantly reduced total and visceral fat and attenuated age-related losses of lean mass in older adults with overweight or obesity and metabolic syndrome. Continued follow-up is warranted to confirm the long-term consequences of these changes on cardiovascular clinical end points.S

First results of the CAST-RADES haloscope search for axions at 34.67 μeV

We present results of the Relic Axion Dark-Matter Exploratory Setup (RADES), a detector which is part of the CERN Axion Solar Telescope (CAST), searching for axion dark matter in the 34.67μeV mass range. A radio frequency cavity consisting of 5 sub-cavities coupled by inductive irises took physics data inside the CAST dipole magnet for the first time using this filter-like haloscope geometry. An exclusion limit with a 95% credibility level on the axion-photon coupling constant of gaγ & 4 × 10−13 GeV−1 over a mass range of 34.6738μeV < ma < 34.6771μeV is set. This constitutes a significant improvement over the current strongest limit set by CAST at this mass and is at the same time one of the most sensitive direct searches for an axion dark matter candidate above the mass of 25μeV. The results also demonstrate the feasibility of exploring a wider mass range around the value probed by CAST-RADES in this work using similar coherent resonant cavitiesWe wish to thank our colleagues at CERN, in particular Marc Thiebert from the coating lab, as well as the whole team of the CERN Central Cryogenic Laboratory for their support and advice in speci c aspects of the project. We thank Arefe Abghari for her contributions as the project's summer student during 2018. This work has been funded by the Spanish Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) under project FPA-2016-76978-C3-2-P and PID2019-108122GB-C33, and was supported by the CERN Doctoral Studentship programme. The research leading to these results has received funding from the European Research Council and BD, JG and SAC acknowledge support through the European Research Council under grant ERC-2018-StG-802836 (AxScale project). BD also acknowledges fruitful discussions at MIAPP supported by DFG under EXC-2094 { 390783311. IGI acknowledges also support from the European Research Council (ERC) under grant ERC-2017-AdG-788781 (IAXO+ project). JR has been supported by the Ramon y Cajal Fellowship 2012-10597, the grant PGC2018-095328-B-I00(FEDER/Agencia estatal de investigaci on) and FSE-GA2017-2019-E12/7R (Gobierno de Aragón/FEDER) (MINECO/FEDER), the EU through the ITN \Elusives" H2020-MSCA-ITN-2015/674896 and the Deutsche Forschungsgemeinschaft under grant SFB-1258 as a Mercator Fellow. CPG was supported by PROMETEO II/2014/050 of Generalitat Valenciana, FPA2014-57816-P of MINECO and by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreements 690575 and 674896. AM is supported by the European Research Council under Grant No. 742104. Part of this work was performed under the auspices of the US Department of Energy by Lawrence Livermore National Laboratory under Contract No. DE-AC52-07NA27344

Formación de los tutores de las prácticas externas como herramienta eficaz en la mejora del aprendizaje del estudiante y su inserción laboral

El objetivo del proyecto es mejorar la calidad de la tutorización de las prácticas externas y fomentar las buenas prácticas que garanticen el proceso de enseñanza-aprendizaje. Están implicados tutores académicos, externos, instituciones y estudiante

Jardins per a la salut

Facultat de Farmàcia, Universitat de Barcelona. Ensenyament: Grau de Farmàcia. Assignatura: Botànica farmacèutica. Curs: 2014-2015. Coordinadors: Joan Simon, Cèsar Blanché i Maria Bosch.Els materials que aquí es presenten són el recull de les fitxes botàniques de 128 espècies presents en el Jardí Ferran Soldevila de l’Edifici Històric de la UB. Els treballs han estat realitzats manera individual per part dels estudiants dels grups M-3 i T-1 de l’assignatura Botànica Farmacèutica durant els mesos de febrer a maig del curs 2014-15 com a resultat final del Projecte d’Innovació Docent «Jardins per a la salut: aprenentatge servei a Botànica farmacèutica» (codi 2014PID-UB/054). Tots els treballs s’han dut a terme a través de la plataforma de GoogleDocs i han estat tutoritzats pels professors de l’assignatura. L’objectiu principal de l’activitat ha estat fomentar l’aprenentatge autònom i col·laboratiu en Botànica farmacèutica. També s’ha pretès motivar els estudiants a través del retorn de part del seu esforç a la societat a través d’una experiència d’Aprenentatge-Servei, deixant disponible finalment el treball dels estudiants per a poder ser consultable a través d’una Web pública amb la possibilitat de poder-ho fer in-situ en el propi jardí mitjançant codis QR amb un smartphone

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality